Supplementary Table 1.
Baseline characteristics for HLA-A groups
| Characteristic | HLA-A |
||
|---|---|---|---|
| Protective (n = 7) | Neutral (n = 39) | Unfavorable (n=57) | |
| Sex, male, n (%) | 7 (100%) | 34 (87%) | 51 (89%) |
| Age, median years (Q1, Q3) | 38 (33, 60) | 42 (36, 48) | 43 (39, 50) |
| Race/Ethnicity, n (%) | |||
| White | 7 (100%) | 24 (62%) | 54 (95%) |
| Black | 0 (0%) | 15 (38%) | 3 (5%) |
| Nadir CD4+ cell count, median cells/μL (Q1, Q3) | 476 (402, 587) | 396 (305, 505) | 422 (350, 566) |
| Pre-ATI CD4+ cell count, median cells/μL (Q1, Q3) | 905 (798, 1161) | 863 (617, 1099) | 832 (681, 1010) |
| Pre-ART viral load, median log10 HIV RNA copies/mL (Q1, Q3) | 4.0 (3.3, 4.7) | 4.4 (3.8, 4.9) | 4.4 (4.0, 4.9) |
| CA-DNA, median log10 copies/106 PBMCs (Q1, Q3) | 2.3 (2.2, 2.9) | 2.4 (1.9, 3.1) | 2.3 (1.7, 2.9) |
| CA-RNA, median log10 copies/106 PBMCs (Q1, Q3) | 2.0 (1.1, 2.6) | 1.7 (1.1, 2.3) | 1.8 (1.1, 2.3) |
| Duration of ART, median years (Q1, Q3) | 3.8 (2.6, 5.3) | 5.4 (3.2, 6.5) | 5.4 (3.3, 7.2) |
| NNRTI-based ART | 4 (57%) | 19 (49%) | 41 (72%) |
| Source study, n (%) | |||
| A5024 | 0 (0%) | 3 (8%) | 4 (7%) |
| A5068 | 0 (0%) | 8 (21%) | 4 (7s%) |
| A5170 | 5 (71%) | 22 (56%) | 35 (61%) |
| A5197 | 2 (29%) | 6 (15%) | 14 (25%) |